Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trace-II: PSMA-radioguided surgery for recurrent prostate cancer
NCT05555017Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2023
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical progression-free survival at 24 months. Status: unknown.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05555017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555017.